(Q36692556)

15 August 2017

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma (English)

1 reference

15 August 2017

0 references

1 reference

4

Thomas F Gajewski

1 reference

15 August 2017

1

Tara C Gangadhar

1 reference

15 August 2017

Joseph I Clark

2

1 reference

PMC publication ID

3600382

15 August 2017

Theodore Karrison

series ordinal

3

1 reference

15 August 2017

15 November 2012

1 reference

Investigational New Drugs

15 August 2017

1 reference

15 August 2017

31

1 reference

15 August 2017

3

1 reference

15 August 2017

769-773

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

30 September 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Src kinases as therapeutic targets for cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3600382

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23151808

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-012-9897-4

1 reference

15 August 2017

1 reference

PMC publication ID

3600382

15 August 2017

PubMed publication ID

23151808

1 reference

PMC publication ID

3600382